Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients
The Postoperative Adjuvant Therapy of Gefitinib for High Risk Stage Ib NSCLC Patients With EGFR Sensitive Mutation, an Open, Paired, Non-interventional, Multi-center Clinical Study
Sponsor: Lunxu Liu
Terminated
Similar study has revealed result of no benefit for participants
Other NSCLC trials with similar outcome
This observational or N/A phase trial investigates NSCLC and is currently terminated or withdrawn. Lunxu Liu leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Terminated NA
Status: Suspended → Terminated
-
Jan 2017 — Jan 2018 [monthly]
Suspended NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lunxu Liu
For direct contact, visit the study record on ClinicalTrials.gov .